Results from the phase 3 RECITE trial show that romiplostim significantly reduces chemotherapy-induced thrombocytopenia, ...

A Nature Cell Biology study shows that vitamin B2 metabolism helps cancer cells evade ferroptosis by stabilizing ferroptosis ...

New findings from the phase III PRIMARY2 trial presented at EAU26 suggest that PSMA PET/CT imaging after inconclusive or reassuring MRI can safely reduce prostate biopsies by about 50 percent without ...

A nationwide U.S. study published in JAMA, analyzing data from 2.15 million women with breast cancer, found that choosing complementary and alternative medicine (CAM) instead of evidence-based therapy ...

Healthcare is entering a new digital era. Yet existing systems still rely on fragmented data and outdated software that struggle to support truly patient-centered care. Real progress now depends on ...

Longer-term follow-up from the Phase 1b/2 OrigAMI-1 study shows that amivantamab (Rybrevant) plus FOLFOX or FOLFIRI achieved a 51% overall response rate in RAS/BRAF wild-type metastatic colorectal ...

Researchers at the Johns Hopkins KCC have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of patients previously lacking precision options. The ...

Researchers at Mass General Brigham engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five immunomodulators, and avoids healthy brain tissue. A single ...

The Phase 3 EV-304 KEYNOTE-B15 trial showed that perioperative enfortumab vedotin (PADCEV) plus pembrolizumab (Keytruda) significantly improved event-free survival and overall survival versus ...

The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated NSCLC, enabling five-minute administration with fewer infusion reactions. In Phase III PALOMA-3, ...

Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median ...